Intracranial hemangiopericytoma (HPC) is rare and aggressive tumor with local recurrences as well as distant metastases. The majority of metastases are encountered in bone, lung, and liver. Pancreatic metastasis is extremely rare. Described in the present report is the case of a 41-year-old woman who had undergone surgical resection of intracranial HPC 16 years earlier. The tumor recurred 3 years after the operation and was successfully managed with surgery followed by adjuvant radiotherapy. Thirteen years later, an isolated pancreatic metastasis developed. Patient underwent Whipple procedure for pancreatic head lesion and received adjuvant radiotherapy. Patient died of extensive disease in lungs, bones, mediastinum, cranium and peritoneal carcinomatosis in abdomen 17 months after pancreatic surgery.
Introduction
Hemangiopericytoma (HPC) is a rare mesenchymal tumor originating from Zimmerman pericytes. [1] It can theoretically be seen anywhere in the human body where capillary bed is present. Soft tissue of lower extremity, pelvis, and retroperitoneum are areas where HPC is most often encountered. Intracranial HPC is rare, with a male predominance in fourth and fifth decades of life, and it is generally related to meningeal tissue. [1, 2] Intracranial HPCs correspond to 2-4% of meningeal tumors and to less than 1% of all central nervous system (CNS) tumors. The most frequent areas of extraneural metastases are bones, lungs, and liver. [3] Pancreatic metastasis is extremely rare. Presently described is the second case reported in the literature with isolated pancreatic metastasis as the first distant metastatic site, which was followed-up with positron emission tomography-computed tomography (PET-CT) imaging.
Case Report
A 41-year-old woman was admitted to general surgery with jaundice. She had no history of alcohol use or smoking. She had no comorbidities. Her father died due to lung cancer. She underwent surgical resection for intracranial HPC 16 years ago. Three years after surgery, a local recurrence developed that was managed with redo surgery followed by adjuvant radiotherapy (RT) (5 fractions of 2 Gy per week, total dose 56 Gy, 2D external RT with Cobalt-60).
Abdominal CT revealed 4x5 cm-sized solid mass in Previous cranial HPC pathology specimen ( Figure  3a ) was re-examined and compared with pancreatic pancreatic head. Locally recurrent disease in cranium was excluded after cranial magnetic resonance imaging (MRI). F-18 fluorodeoxyglucose (18-FDG) PET/ CT imaging pointed to pancreatic head with slightly increased FDG uptake (SUVmax=4.2) in the mass (Figure 1a, b) . There was no distant metastasis in PET/ CT images.
Patient underwent standard Whipple procedure with lymphadenectomy. Histopathological examination showed 6x6x4.5 cm-sized malignant pancreatic HPC (Figure 2) , with lymphovascular invasion. Mass was excised with negative surgical margins. Lymph node involvement was negative in 22 excised lymph nodes. 
Discussion
Intracranial HPCs demonstrate clinically and biologically aggressive behavior even after radical surgery followed by adjuvant RT. Local recurrences (up to 90%) and extracranial metastases (up to 33%) are frequent. [4] [5] [6] The most frequent areas of extraneural metastases are bones, lungs, and liver. [3] Whereas preferred treatment for intracranial HPC is surgical resection, the chance for definite cure is very low with surgery alone. Intracranial HPC is known as a radiosensitive tumor. There is some research on role of adjuvant RT in treatment of recurrent intracranial HPCs. [7, 8] Hypervascular tumors are reported to be prone to bleed intraoperatively with high mortality rates (9-24%) for intracranial HPCs. [9, 10] Complete resection in the initial operation has been found to be highly correlated with long survival and late recurrence rates. Due to high risk of intracranial and extracranial metastases after surgical resection, it is suggested that RT be added to surgery in the treatment of intracranial HPCs. [4, 8] Guthrie et al. [3] reported progression-free survival as 74 months in irradiated, and 29 months in nonirradiated patients after surgery for HPCs. Doses of irradiation higher than 50 Gy have been recommended to avoid early recurrence and for local control after surgery. [10, 11] Recently, Ghia et al. [12] demonstrated better local control in their study that included 63 intracranial HPC patients who received RT doses of more than 60 Gy following total resection of tumor. The most common metastatic sites are bone, liver, lungs, abdominal cavity, lymph nodes, skeletal muscle, kidneys, pancreas, skin, subcutaneous tissue, breast, adrenal glands, gallbladder, diaphragm, retroperitoneum, and heart. Meredith [20] 44 F Bone, (liver, lung, mediastinum, pancreas autopsy) Yes Pitkethly [22] ND ND Pancreas (4 cases) ND Kepes [17] 40 M Lung, kidney, liver, pancreas 1 year ago Akagi [13] 42 F Lung, liver, pancreas, vertebra Yes Palacios [21] 40 M Lung (pancreas, kidney autopsy) Yes Jestico [16] 47 M Kidney, lymph node, liver, pancreas Yes Tanabe [24] 65 M Pancreas Yes Arita [14] 57 M Bone (pancreas, kidney, spinal cord 4 years ago multiple metastases at the autopsy) intracranial masses Iwaki [15] 40 M Lung, liver, bone, lymph node ND Iwaki [15] 64 M Pancreas No Mena [19] ND ND 2 cases pancreas ND Koyama [18] 55 M Liver, lung, bone, pancreas 3 years ago Galanis [6] ND ND Pancreas (1 case) ND Niwa [25] 55 M Liver, lung,vertebra, pancreas ND Suziki [23] 65 M Bone, pancreas Yes Galambos [5] 58 M Lung, pancreas Last recurrence 5 year ago Hoshi [26] 45 F Bone, pancreas ND Trout [2] 67 F Pancreas Yes Hiraide [27] 65 M Lung, kidney, pancreas Last recurrence 2 year ago Ramos [28] 52 [27] reported on variable intervals (9-24 years) between initial diagnosis and manifestation of pancreatic metastasis. All 12 of their patients died in the first year after detection of pancreatic metastasis secondary to intracranial HPC. [27] The patient with meningeal HPC in our case report was diagnosed 16 years after initial diagnosis and surgery with solitary pancreatic metastasis and died 17 months after pancreatic resection.
Local recurrences as well as distant metastases frequently accompany intracranial HPC. This is an aggressive disease and lifelong follow-up after curative surgery and/or adjuvant radiotherapy should be taken into account. The possibility of late, distant metastasis of intracranial HPC, even in pancreas, without local recurrences should be kept in mind. PET/CT is an effective screening modality for metastasis. Pancreatic metastasis seems to be associated with poor survival rate.
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